CSIMarket Company Name, Ticker, Competitors, else..
 
Eyepoint Pharmaceuticals Inc   (NASDAQ: EYPT)
Other Ticker:  
 
 
Price: $10.3000 $0.24 2.386%
Day's High: $10.58 Week Perf: -0.58 %
Day's Low: $ 10.03 30 Day Perf: 14.06 %
Volume (M): 477 52 Wk High: $ 13.99
Volume (M$): $ 4,918 52 Wk Avg: $8.06
Open: $10.03 52 Wk Low: $3.91



 Market Capitalization (Millions $) 719
 Shares Outstanding (Millions) 70
 Employees 63
 Revenues (TTM) (Millions $) 56
 Net Income (TTM) (Millions $) -147
 Cash Flow (TTM) (Millions $) -186
 Capital Exp. (TTM) (Millions $) 3

Eyepoint Pharmaceuticals Inc
Eyepoint Pharmaceuticals Inc is a specialty biopharmaceutical company that focuses on developing innovative and sustained-release therapeutics for treating various eye diseases. The company's primary goal is to improve patient outcomes and provide more convenient treatment options for ophthalmic conditions. Eyepoint employs advanced technology to develop unique drug delivery systems that can achieve long-lasting therapeutic effects with a single dose. Their product portfolio includes treatments for conditions such as macular edema, posterior uveitis, and other retinal diseases. Eyepoint Pharmaceuticals aims to transform the treatment landscape for eye diseases and enhance the quality of life for patients.


   Company Address: 480 Pleasant Street Watertown 2472 MA
   Company Phone Number: 926-5000   Stock Exchange / Ticker: NASDAQ EYPT


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
GKOS      % 
HROW      % 
KPRX      % 
OCUL      % 
REGN      % 
TARS      % 
• View Complete Report
   



Shares

EyePoint Pharmaceuticals Strengthens Employee Incentives with Stock Options Amid Financial Growth and Public Offering Success,

Published Mon, Mar 17 2025 11:00 AM UTC

EyePoint Pharmaceuticals Expands Employee Incentives and Strengthens Financial Position Amid Market ActivityWATERTOWN, Mass. March 17, 2025 EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company devoted to the development and commercialization of innovative therapeutics designed to enhance the quality of life for patients affected by serious retinal diseases, has recent...
Stock Market Announcement

Talent in Focus: EyePoint Pharmaceuticals Inducement Grants Spur Growth Potential Despite Dilution Risks,

Published Mon, Feb 17 2025 12:00 PM UTC

EyePoint Pharmaceuticals Boosts Talent with Inducement Grants: What It Means for InvestorsIn a significant move that reflects its continued commitment to fostering growth and attracting talent, EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) recently announced the granting of non-statutory stock options to new employees as part of their efforts to enhance their workforce. Thi...
Management Announcement

EyePoint Provides Company Update and Anticipated Development Milestones for 2025

Published Mon, Jan 13 2025 12:01 PM UTC

EyePoint Pharmaceuticals: Strategic Growth and Promising Developments in OphthalmologyIn an era where the pharmaceutical industry faces rigorous competition and rapid advancements, EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) is making noteworthy progress in its quest to provide innovative solutions for serious retinal diseases. The company?s latest updates reveal a strate...
Shares

EyePoint Pharmaceuticals? $140 Million Upsized Public Offering Marks Strategic Growth and Market Resurgence,

Published Wed, Oct 30 2024 1:48 AM UTC

EyePoint Pharmaceuticals Announces Pricing of Upsized Public Offering: A Strategic Leap Towards Growth and InnovationWatertown, Mass. October 29, 2024 EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pivotal player in the realm of healthcare innovation, has recently taken significant strides to fortify its growth trajectory. Committed to developing life-enhancing therapeut...
Management Announcement

EyePoint Pharmaceuticals Initiates $100 Million Public Offering, Upsizes to $140 Million to Fuel Growth in Retinal Disease Treatments,

Published Mon, Oct 28 2024 9:14 PM UTC

EyePoint Pharmaceuticals Expands Growth Horizon with Major Public Offering: Insights and ImplicationsOn October 28, 2024, EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pioneering company focused on innovative therapeutics for retinal diseases, announced its intention to initiate an underwritten public offering of common stock worth $100 million. This strategic move under...






Eyepoint Pharmaceuticals Inc's Segments

  Eyepoint Pharmaceuticals Inc Outlook

On March 7 2024 the Eyepoint Pharmaceuticals Inc provided following guidance

EyePoint Pharmaceuticals Inc. has released their financial results for the fourth quarter and full year of 2023, along with highlighting recent corporate developments. One of the most significant updates includes the announcement of positive topline efficacy and safety data from the Phase 2 DAVIO 2 trial of EYP-1901 in wet age-related macular degeneration (AMD). This study successfully met all primary and secondary endpoints, marking a significant milestone for the company.

Following these promising results, EyePoint Pharmaceuticals Inc. anticipates initiating the first Phase 3 clinical trial for EYP-1901 in the second half of 2024. This advancement in the development of EYP-1901 highlights the compan...





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com